Skip to main content
| News

Alentis secures 67 million US dollars

18.06.2021

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds will be deployed to develop its pipeline of drugs treating advanced liver and kidney fibrosis.

Thomas Baumert, Founder and Executive BoD

Alentis Therapeutics develops anti-fibrotic molecules to treat advanced liver and kidney fibrosis and also, by means of its proprietary platform, works on programs targeting other fibrotic diseases and hepatobiliary cancers.

Now, the Basel-based biotechnology company has secured 67 million US dollars in a series B funding round according to a press release. This will be used to bring Alentis’s lead product, monoclonal antibodies targeting claudin-1through a proof-of-concept study. Professor Thomas Baumert of the University of Strasbourg, who founded Alentis, is quoted in the press release, saying: “Fibrosis is an important risk factor for cancer, and Claudin-1 has a well-established role in cancer biology including tumor invasion and metastasis. Given the absent and unsatisfactory treatment options, it’s critical that we deliver new therapeutics for patients suffering from fibrosis and cancer.”

BaseLaunch, the biotech incubator and accelerator of Basel Area Business & Innovation, provided Alentis with decisive support during its founding phase and helped setting up the company in Basel. The funding round was led by Morningside Venture Investments and joined by Jeito Capital as well as the the Series A investors.

Jason Dinges from Morningside and Rafaèle Tordjman, Founder and CEO of Jeito Capital, have been welcomed to the Board of Directors. “Alentis has an outstanding and experienced team from pharma and biotech and is focused on a unique target, based on the founder’s work and his team of more than 10 years,” Tordjman is quoted as saying in the press release. Alentis Therapeutics plans to start the first clinical trials in Q4 2021.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Cell and gene therapies gain momentum in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
AMR Action Fund invests in new antibiotics developed by BioVersys
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Investors give Resistell 8.5 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
BSI integrating AI from Parashift in banking software
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

BSI integrating AI from Parashift in banking software

Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.